348 related articles for article (PubMed ID: 10430609)
1. Mixed chimerism induced without lethal conditioning prevents T cell- and anti-Gal alpha 1,3Gal-mediated graft rejection.
Ohdan H; Yang YG; Shimizu A; Swenson KG; Sykes M
J Clin Invest; 1999 Aug; 104(3):281-90. PubMed ID: 10430609
[TBL] [Abstract][Full Text] [Related]
2. Tolerization of Gal alpha 1,3Gal-reactive B cells in pre-sensitized alpha 1,3-galactosyltransferase-deficient mice by nonmyeloablative induction of mixed chimerism.
Ohdan H; Swenson KG; Kitamura H; Yang YG; Sykes M
Xenotransplantation; 2001 Nov; 8(4):227-38. PubMed ID: 11737848
[TBL] [Abstract][Full Text] [Related]
3. T cell and B cell tolerance to GALalpha1,3GAL-expressing heart xenografts is achieved in alpha1,3-galactosyltransferase-deficient mice by nonmyeloablative induction of mixed chimerism.
Ohdan H; Yang YG; Swenson KG; Kitamura H; Sykes M
Transplantation; 2001 Jun; 71(11):1532-42. PubMed ID: 11435961
[TBL] [Abstract][Full Text] [Related]
4. Sequential analysis of anti-alpha Gal natural antibody-producing B cells in GalT knockout mice in cyclophosphamide-induced tolerance.
Shimizu I; Tomita Y; Iwai T; Kajiwara T; Okano S; Nomoto K; Tominaga R
Scand J Immunol; 2006 Jun; 63(6):435-43. PubMed ID: 16764697
[TBL] [Abstract][Full Text] [Related]
5. Application of cyclophosphamide-induced tolerance in alpha1,3-galactosyltransferase knockout mice presensitized with Gal alpha 1-3Gal beta-4-GlcNAc antigens.
Onzuka T; Shimizu I; Tomita Y; Iwai T; Okano S; Tominaga R
Surg Today; 2008; 38(9):807-14. PubMed ID: 18751946
[TBL] [Abstract][Full Text] [Related]
6. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
7. Tolerization of anti-Galalpha1-3Gal natural antibody-forming B cells by induction of mixed chimerism.
Yang YG; deGoma E; Ohdan H; Bracy JL; Xu Y; Iacomini J; Thall AD; Sykes M
J Exp Med; 1998 Apr; 187(8):1335-42. PubMed ID: 9547344
[TBL] [Abstract][Full Text] [Related]
8. Differing mechanisms of early and late B cell hyporesponsiveness induced by mixed chimerism.
Kawahara T; Shimizu I; Ohdan H; Zhao G; Sykes M
Am J Transplant; 2005 Dec; 5(12):2821-9. PubMed ID: 16302994
[TBL] [Abstract][Full Text] [Related]
9. Additional monoclonal antibody (mAB) injections can replace thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti-T cell mABs and 3-Gy whole body irradiation.
Tomita Y; Sachs DH; Khan A; Sykes M
Transplantation; 1996 Feb; 61(3):469-77. PubMed ID: 8610363
[TBL] [Abstract][Full Text] [Related]
10. Prevention of chronic rejection in murine cardiac allografts: a comparison of chimerism- and nonchimerism-inducing costimulation blockade-based tolerance induction regimens.
Shirasugi N; Adams AB; Durham MM; Lukacher AE; Xu H; Rees P; Cowan SR; Williams MA; Pearson TC; Larsen CP
J Immunol; 2002 Sep; 169(5):2677-84. PubMed ID: 12193741
[TBL] [Abstract][Full Text] [Related]
11. Xenotransplantation and ABO incompatible transplantation: the similarities they share.
Galili U
Transfus Apher Sci; 2006 Aug; 35(1):45-58. PubMed ID: 16905361
[TBL] [Abstract][Full Text] [Related]
12. Use of lentiviral vectors to induce long-term tolerance to gal(+) heart grafts.
Kearns-Jonker M; Fischer-Lougheed J; Shulkin I; Kleihauer A; Mitsuhashi N; Kohn DB; Weinberg K; D'Apice AJ; Starnes VA; Cramer DV
Transplantation; 2004 Jun; 77(11):1748-54. PubMed ID: 15201677
[TBL] [Abstract][Full Text] [Related]
13. CTLA4-Ig-based conditioning regimen to induce tolerance to cardiac allografts.
Li S; Salgar SK; Thanikachalam M; Murdock AD; Gammie JS; Demetris AJ; Zeevi A; Pham SM
J Surg Res; 2006 Dec; 136(2):238-46. PubMed ID: 17046021
[TBL] [Abstract][Full Text] [Related]
14. Graft-versus-host-reactive donor CD4 cells can induce T cell-mediated rejection of the donor marrow in mixed allogeneic chimeras prepared with nonmyeloablative conditioning.
Kim YM; Mapara MY; Down JD; Johnson KW; Boisgerault F; Akiyama Y; Benichou G; Pelot M; Zhao G; Sykes M
Blood; 2004 Jan; 103(2):732-9. PubMed ID: 14512313
[TBL] [Abstract][Full Text] [Related]
15. Innate and adaptive immune responses are tolerized in chimeras prepared with nonmyeloablative conditioning.
Xu H; Zhu Z; Huang Y; Bozulic LD; Hussain LR; Yan J; Ildstad ST
Transplantation; 2012 Mar; 93(5):469-76. PubMed ID: 22228418
[TBL] [Abstract][Full Text] [Related]
16. Immune tolerance to combined organ and bone marrow transplants after fractionated lymphoid irradiation involves regulatory NK T cells and clonal deletion.
Higuchi M; Zeng D; Shizuru J; Gworek J; Dejbakhsh-Jones S; Taniguchi M; Strober S
J Immunol; 2002 Nov; 169(10):5564-70. PubMed ID: 12421933
[TBL] [Abstract][Full Text] [Related]
17. Mechanism by which additional monoclonal antibody (mAB) injections overcome the requirement for thymic irradiation to achieve mixed chimerism in mice receiving bone marrow transplantation after conditioning with anti-T cell mABs and 3-Gy whole body irradiation.
Tomita Y; Khan A; Sykes M
Transplantation; 1996 Feb; 61(3):477-85. PubMed ID: 8610364
[TBL] [Abstract][Full Text] [Related]
18. High antigen levels do not preclude B-cell tolerance induction to alpha1,3-Gal via mixed chimerism.
Haspot F; Bardwell PD; Zhao G; Sykes M
Xenotransplantation; 2008; 15(5):313-20. PubMed ID: 19134161
[TBL] [Abstract][Full Text] [Related]
19. Thymic dependence of loss of tolerance in mixed allogeneic bone marrow chimeras after depletion of donor antigen. Peripheral mechanisms do not contribute to maintenance of tolerance.
Khan A; Tomita Y; Sykes M
Transplantation; 1996 Aug; 62(3):380-7. PubMed ID: 8779687
[TBL] [Abstract][Full Text] [Related]
20. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen.
Tomita Y; Khan A; Sykes M
J Immunol; 1994 Aug; 153(3):1087-98. PubMed ID: 8027542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
